Recently, HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD. and its parent company, Ascenda Pte. Ltd. (hereinafter referred to as ShanZeBIO), formally signed a strategic cooperation agreement for import distribution with Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (hereinafter referred to as SPH Kyuan Trade). The two parties announced that they will engage in in-depth cooperation centered on ShanZeBIO’s key product, Moxifloxacin Hydrochloride and Sodium Chloride Injection (brand name: Avelox®).
Avelox® is a fluoroquinolone antibiotic that was first approved for marketing in Europe and the United States in 1999 and entered the Chinese market in 2002; it has served Chinese patients for over 20 years to date. Currently, this product has benefited more than 240 million patients in over 100 countries worldwide.
The establishment of this strategic partnership marks an important beginning for the two parties to deepen their cooperation in the Chinese pharmaceutical market. SPH Kyuan Trade will fully leverage its comprehensive capabilities in import customs clearance, warehousing and distribution, market access, and channel expansion to help Avelox® serve Chinese medical institutions and patients more efficiently and reliably, and will partner with ShanZeBIO to promote the sustainable development of high-quality pharmaceutical products in China.
About HANGZHOU SHANZE BIOPHARMACEUTICAL CO., LTD.
ShanZeBIO is an innovative biopharmaceutical company invested by HSG. The company focuses on anti-infectives, respiratory diseases and critical care. Through a model that combines “mature product operations with innovative R&D and technology introduction”, it is committed to delivering sustainable medical solutions for patients worldwide.
About Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd.
Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (hereinafter referred to as “SPH Kyuan Trade”) is a core pharmaceutical import and distribution enterprise of SPH Kyuan affiliated to Shanghai Pharma Group, which has been listed in the Fortune Global 500 for many consecutive years. Established in Beijing Tianzhu Comprehensive Bonded Zone in 2009, it is a large, diversified, comprehensive service-oriented pharmaceutical enterprise integrating bonded imports, pharmaceutical distribution, vaccine services, digital marketing, market access, and supply chain extension services. With nationwide operations, the company has consistently achieved an annual growth rate above the industry average. Guided by the corporate culture of “Taking Pride in Our Services”, the company is dedicated to serving the industry, its partners, and the public, and strives to become a world-class, technology-driven healthcare service enterprise.
